Why China’s next success story may be healthcare

China’s electric vehicle (EV) boom showed how fast a new industry can globalize when policy ambition, supply chain strength and consumer demand align. Healthcare will test a harder question: whether innovation can travel across health systems.

This is not another EV story. Healthcare does not globalize on cost, scale or manufacturing quality alone. A medicine, diagnostic tool, medical device or AI-enabled care model must meet a higher bar. It needs clinical evidence, regulatory confidence, ethical data governance and patient acceptance.

That makes healthcare one of the most important tests of China’s next phase of globalization. Over the past decade, China has shown how quickly scale can reshape industries, from high-speed rail and mobile payments to e-commerce and electric vehicles. In healthcare, the challenge is different. Scale must become evidence. Speed must become safety. Innovation must become adoption.

Three shifts are bringing this question into focus.

China’s next phase of growth is expected to rely less on traditional industrial expansion and more on advanced technology, science and productivity. Healthcare sits squarely within that transition.

Biotechnology, medical devices, digital health and advanced manufacturing are likely to receive stronger policy attention during the 15th Five-Year Plan period. This matters because healthcare innovation depends on more than capital and scientific discovery. Regulation, clinical infrastructure, reimbursement, talent and public health priorities all have to move together.

China’s ageing society adds urgency. By the end of 2025, China had 323.38 million people aged 60 and above, accounting for 23.0% of the population, according to the National Bureau of Statistics. China also aims to raise average life expectancy to around 80 years during the 2026 to 2030 period, up from 79 years at the end of 2024, according to the National Health Commission.

This changes the innovation agenda. The question is no longer only how to treat disease, but how to help people live longer, healthier and more independent lives. That means more focus on prevention, early detection, chronic disease management, rehabilitation, home-based services and digital health.

For China, healthcare innovation is not just an industrial opportunity. It is becoming a demographic necessity.

China has one of the world’s largest health systems. Basic medical insurance covered around 95% of the population during the 2021 to 2025 period, with more than 1.32 billion people enrolled in 2024, according to the National Healthcare Security Administration. This gives innovators a vast market, deep clinical demand and an increasingly digital foundation for experimentation.

Scale has powered many of China’s most recognizable transformations. In mobile payments and e-commerce, large user bases enabled rapid iteration. In electric vehicles, domestic demand helped companies refine products, strengthen supply chains and reduce costs.

Healthcare could benefit from similar dynamics, but only if scale is converted into better evidence and better outcomes.

This is especially important as artificial intelligence (AI) moves deeper into health systems. AI could support earlier diagnosis, clinical decision-making, hospital operations, drug discovery, remote monitoring and chronic disease management. For a country facing ageing, uneven access to care and rising demand, the potential is significant.

But health data is not consumer data. Large datasets only create value when they are accurate, secure, interoperable and clinically meaningful. The next test for China’s digital health system is whether it can move from being data rich to evidence rich.

The third shift is corporate. A new generation of healthcare companies is emerging from China’s innovation ecosystem, but many are not simply “Chinese companies going global”. They are being built as globally native companies from the start.

Their science may begin in China. But their capital, clinical trials, partnerships, licensing strategies and investor base increasingly span markets. They are earning abroad, raising abroad and designing themselves for global validation.

This is already visible in biotechnology. Companies in the Greater China region, including mainland China, Hong Kong, Macau and Taiwan, completed 186 cross-border out-licensing deals in 2025, with total value reaching $137.7 billion, according to PharmCube data reported by Reuters.

But the deeper story is not the deal value. It is the operating model.

Earlier waves of Chinese globalization were often about exporting products after winning at home. In healthcare, some companies are now thinking globally from day one: designing trials for international regulators, partnering with multinational firms, engaging global investors and building evidence for multiple markets.

This changes the meaning of internationalization. It is no longer only about selling overseas. It is about building science, governance and credibility across borders from the beginning.

The opportunity is large. But progress will not be automatic.

The first test is regulation. Healthcare innovation is moving faster than many of the systems built to govern it. AI diagnostics, digital therapeutics, connected devices, cell therapies and gene therapies do not fit neatly into old categories. They sit across drugs, devices, software and services.

For China, coordination will be crucial. Approval, reimbursement and clinical adoption are overseen by different institutions. If these systems do not align, innovation may move quickly in the lab but slowly in hospitals.

The second test is data governance. AI-enabled healthcare depends on sensitive health data, including clinical, genomic and behavioural information. Cross-border data flows, patient consent, cybersecurity, algorithmic transparency and genetic data protection will shape whether Chinese-origin innovations can be adopted globally.

The third test is adoption. Healthcare innovations must work in real world systems, not only in pilots or controlled settings. They must fit clinical workflows, reimbursement models, physician behaviour and patient needs. For Chinese-origin innovations seeking global relevance, evidence will need to travel as convincingly as the product.

China has many of the ingredients for a globally relevant healthcare innovation ecosystem: policy momentum, an ageing population, deep clinical demand, digital infrastructure, manufacturing strength and a growing base of science-led companies.

The question is whether these ingredients can produce innovations that work beyond China.

That is what makes healthcare different from earlier globalization stories. In EVs, success can be measured in exports, market share and cost competitiveness. In healthcare, success is measured in outcomes, safety, evidence and adoption.

If China can match industrial ambition with responsible governance, healthcare could become more than its next global growth industry. It could help health systems everywhere respond to ageing populations, chronic disease, workforce shortages and rising costs.

China has shown that it can scale industries quickly. Healthcare will show whether it can scale innovation responsibly across borders.